Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - GALECTIN THERAPEUTICS INC | d314087dex322.htm |
| EX-31.2 - EX-31.2 - GALECTIN THERAPEUTICS INC | d314087dex312.htm |
| EX-31.1 - EX-31.1 - GALECTIN THERAPEUTICS INC | d314087dex311.htm |
| EX-23.1 - EX-23.1 - GALECTIN THERAPEUTICS INC | d314087dex231.htm |
| EX-21.1 - EX-21.1 - GALECTIN THERAPEUTICS INC | d314087dex211.htm |
| 10-K - FORM 10-K - GALECTIN THERAPEUTICS INC | d314087d10k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-K for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter G. Traber, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| March 28, 2017 | /s/ Peter G. Traber | |||||
| Name: | Peter G. Traber, M.D. | |||||
| Title: | Chief Executive Officer and President (principal executive officer) | |||||